CN107266467A - 用作ampk的活化剂的噻吩并吡啶酮衍生物 - Google Patents

用作ampk的活化剂的噻吩并吡啶酮衍生物 Download PDF

Info

Publication number
CN107266467A
CN107266467A CN201710493350.XA CN201710493350A CN107266467A CN 107266467 A CN107266467 A CN 107266467A CN 201710493350 A CN201710493350 A CN 201710493350A CN 107266467 A CN107266467 A CN 107266467A
Authority
CN
China
Prior art keywords
compound
pyridine
chloro
thienos
bases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710493350.XA
Other languages
English (en)
Chinese (zh)
Inventor
D·克拉沃
S·阿拉库-博泽克
S·博尔兹
F·勒皮弗尔
L·法韦里尔
J-D·迪朗
C·卡龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poxel SA
Original Assignee
Poxel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel SA filed Critical Poxel SA
Publication of CN107266467A publication Critical patent/CN107266467A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201710493350.XA 2012-06-29 2013-06-28 用作ampk的活化剂的噻吩并吡啶酮衍生物 Pending CN107266467A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305775.4A EP2679591A1 (en) 2012-06-29 2012-06-29 Thienopyridone derivatives useful as activators of AMPK
EP12305775.4 2012-06-29
CN201380034638.0A CN104395319B (zh) 2012-06-29 2013-06-28 用作ampk的活化剂的噻吩并吡啶酮衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380034638.0A Division CN104395319B (zh) 2012-06-29 2013-06-28 用作ampk的活化剂的噻吩并吡啶酮衍生物

Publications (1)

Publication Number Publication Date
CN107266467A true CN107266467A (zh) 2017-10-20

Family

ID=48703549

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710493350.XA Pending CN107266467A (zh) 2012-06-29 2013-06-28 用作ampk的活化剂的噻吩并吡啶酮衍生物
CN201380034638.0A Active CN104395319B (zh) 2012-06-29 2013-06-28 用作ampk的活化剂的噻吩并吡啶酮衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380034638.0A Active CN104395319B (zh) 2012-06-29 2013-06-28 用作ampk的活化剂的噻吩并吡啶酮衍生物

Country Status (26)

Country Link
US (1) US9284329B2 (cg-RX-API-DMAC7.html)
EP (2) EP2679591A1 (cg-RX-API-DMAC7.html)
JP (1) JP5972460B2 (cg-RX-API-DMAC7.html)
KR (1) KR101704448B1 (cg-RX-API-DMAC7.html)
CN (2) CN107266467A (cg-RX-API-DMAC7.html)
AU (1) AU2013283239B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014032526B1 (cg-RX-API-DMAC7.html)
CA (1) CA2876789C (cg-RX-API-DMAC7.html)
CY (1) CY1118213T1 (cg-RX-API-DMAC7.html)
DK (1) DK2867240T3 (cg-RX-API-DMAC7.html)
EA (1) EA026300B1 (cg-RX-API-DMAC7.html)
ES (1) ES2603737T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161482T1 (cg-RX-API-DMAC7.html)
HU (1) HUE030946T2 (cg-RX-API-DMAC7.html)
IL (1) IL236221A (cg-RX-API-DMAC7.html)
IN (1) IN2014MN02661A (cg-RX-API-DMAC7.html)
LT (1) LT2867240T (cg-RX-API-DMAC7.html)
ME (1) ME02537B (cg-RX-API-DMAC7.html)
MX (1) MX359221B (cg-RX-API-DMAC7.html)
PL (1) PL2867240T3 (cg-RX-API-DMAC7.html)
PT (1) PT2867240T (cg-RX-API-DMAC7.html)
RS (1) RS55308B1 (cg-RX-API-DMAC7.html)
SI (1) SI2867240T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600418B (cg-RX-API-DMAC7.html)
WO (1) WO2014001554A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500593B (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108516972A (zh) * 2018-05-30 2018-09-11 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
CN114727979A (zh) * 2019-11-27 2022-07-08 雀巢产品有限公司 二苯并吡喃ampk活化剂化合物、组合物、方法及其用途
CN115335048A (zh) * 2020-03-26 2022-11-11 博希尔公司 噻吩并吡啶酮衍生物在治疗肾上腺脑白质营养不良或肾上腺脊髓神经病中的用途
CN115361949A (zh) * 2020-04-02 2022-11-18 博希尔公司 噻吩并吡啶酮衍生物在治疗常染色体显性多囊肾病adpkd中的用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105078992B (zh) * 2014-05-23 2017-11-21 资元堂生物科技股份有限公司 异喹啉生物碱衍生物用于制备促进ampk活性的药物的用途
CN105037321A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途
CN104910130A (zh) * 2015-06-23 2015-09-16 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和氨基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104892569A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途
CN104945370A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104945369A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104910129A (zh) * 2015-06-23 2015-09-16 佛山市赛维斯医药科技有限公司 含六甲基苯环和卤代苯结构的黄原酸酯类化合物、其制备方法及用途
CN104892568A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途
CN105001181A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一类双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104945371A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926755A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途
CN105037296A (zh) * 2015-06-24 2015-11-11 佛山市赛维斯医药科技有限公司 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104945372A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926756A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途
CN104926757A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途
CN105541715B (zh) * 2016-02-02 2019-04-09 浙江工业大学 多取代吡啶-1(2h)-酮衍生物及其合成方法与应用
KR101925020B1 (ko) 2017-04-21 2018-12-04 연세대학교 산학협력단 Mkrn1의 발현 또는 활성 억제제를 유효성분으로 함유하는, 대사성 질환의 예방 및 치료용 약학적 조성물
EA202091897A1 (ru) * 2018-02-08 2020-10-27 Энио Фарма Неконденсированные производные тиофена и их применение
KR102663976B1 (ko) * 2018-11-16 2024-05-09 폭셀 에스아 티에노피리돈 유도체의 1수화물 칼륨염 및 이의 제조 방법
US20220184172A1 (en) * 2019-04-19 2022-06-16 The Regents Of The University Of California Ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
WO2021037702A1 (en) 2019-08-28 2021-03-04 Poxel Pharmaceutical combination of a specific thienopyridone derivative with an fxr agonist for the treatment of liver diseases
WO2021198284A1 (en) 2020-03-30 2021-10-07 Poxel Use of a thienopyridone derivative in the treatment of cardiovascular diseases
ES3010512T3 (en) 2020-03-30 2025-04-03 Poxel Use of a thienopyridone derivative in the treatment of diabetic nephropathy
WO2021204751A1 (en) 2020-04-06 2021-10-14 Poxel Pharmaceutical combination for the treatment of liver diseases
WO2021204755A1 (en) 2020-04-06 2021-10-14 Poxel Pharmaceutical combination for the treatment of liver diseases
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN116322663A (zh) 2020-09-30 2023-06-23 比奥维拉迪维治疗股份有限公司 Ampk激活剂及其使用方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1133843A (zh) * 1994-12-15 1996-10-23 默克专利股份有限公司 噻吩并吡啶酮
US20050038068A1 (en) * 2003-05-16 2005-02-17 Iyengar Rajesh R. Thienopyridones as AMPK activators for the treatment of diabetes and obesity
CN101061123A (zh) * 2004-10-07 2007-10-24 Epix特拉华公司 噻吩并吡啶酮化合物及治疗方法
CN101232883A (zh) * 2005-08-18 2008-07-30 默克专利有限公司 作为ampk激活剂的噻吩并吡啶酮衍生物的用途及包含它们的药物组合物
CN101998853A (zh) * 2008-04-11 2011-03-30 默克专利有限公司 作为amp-活化的蛋白激酶(ampk)激活剂的噻吩并吡啶酮衍生物
CN102015676A (zh) * 2008-05-05 2011-04-13 默克专利有限公司 作为amp-活化的蛋白激酶(ampk)活化剂的噻吩并吡啶酮衍生物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1133843A (zh) * 1994-12-15 1996-10-23 默克专利股份有限公司 噻吩并吡啶酮
US20050038068A1 (en) * 2003-05-16 2005-02-17 Iyengar Rajesh R. Thienopyridones as AMPK activators for the treatment of diabetes and obesity
CN101061123A (zh) * 2004-10-07 2007-10-24 Epix特拉华公司 噻吩并吡啶酮化合物及治疗方法
CN101232883A (zh) * 2005-08-18 2008-07-30 默克专利有限公司 作为ampk激活剂的噻吩并吡啶酮衍生物的用途及包含它们的药物组合物
CN101998853A (zh) * 2008-04-11 2011-03-30 默克专利有限公司 作为amp-活化的蛋白激酶(ampk)激活剂的噻吩并吡啶酮衍生物
CN102015676A (zh) * 2008-05-05 2011-04-13 默克专利有限公司 作为amp-活化的蛋白激酶(ampk)活化剂的噻吩并吡啶酮衍生物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108516972A (zh) * 2018-05-30 2018-09-11 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
CN114727979A (zh) * 2019-11-27 2022-07-08 雀巢产品有限公司 二苯并吡喃ampk活化剂化合物、组合物、方法及其用途
CN115335048A (zh) * 2020-03-26 2022-11-11 博希尔公司 噻吩并吡啶酮衍生物在治疗肾上腺脑白质营养不良或肾上腺脊髓神经病中的用途
CN115335048B (zh) * 2020-03-26 2025-04-04 博希尔公司 噻吩并吡啶酮衍生物在治疗肾上腺脑白质营养不良或肾上腺脊髓神经病中的用途
CN115361949A (zh) * 2020-04-02 2022-11-18 博希尔公司 噻吩并吡啶酮衍生物在治疗常染色体显性多囊肾病adpkd中的用途

Also Published As

Publication number Publication date
EP2867240A1 (en) 2015-05-06
KR101704448B1 (ko) 2017-02-08
US9284329B2 (en) 2016-03-15
HUE030946T2 (en) 2017-06-28
IL236221A0 (en) 2015-02-01
BR112014032526B1 (pt) 2022-11-01
EP2867240B1 (en) 2016-09-14
IN2014MN02661A (cg-RX-API-DMAC7.html) 2015-08-28
EA026300B1 (ru) 2017-03-31
SI2867240T1 (sl) 2017-01-31
MX2014016107A (es) 2015-11-16
IL236221A (en) 2017-12-31
MX359221B (es) 2018-09-18
EA201500064A1 (ru) 2015-08-31
CA2876789C (en) 2017-01-31
LT2867240T (lt) 2016-12-27
KR20150033709A (ko) 2015-04-01
BR112014032526A2 (pt) 2017-06-27
ZA201500593B (en) 2016-01-27
EP2679591A1 (en) 2014-01-01
CN104395319B (zh) 2017-10-27
AU2013283239B2 (en) 2016-01-28
JP2015521651A (ja) 2015-07-30
WO2014001554A1 (en) 2014-01-03
DK2867240T3 (en) 2016-12-05
CY1118213T1 (el) 2017-06-28
US20150166566A1 (en) 2015-06-18
AU2013283239A1 (en) 2015-01-22
ES2603737T3 (es) 2017-03-01
HRP20161482T1 (hr) 2016-12-30
PL2867240T3 (pl) 2017-02-28
CA2876789A1 (en) 2014-01-03
CN104395319A (zh) 2015-03-04
PT2867240T (pt) 2016-11-24
RS55308B1 (sr) 2017-03-31
JP5972460B2 (ja) 2016-08-17
ME02537B (me) 2017-02-20
SMT201600418B (it) 2017-01-10

Similar Documents

Publication Publication Date Title
CN104395319B (zh) 用作ampk的活化剂的噻吩并吡啶酮衍生物
US20250197379A1 (en) Novel ras inhibitors
CN106536520B (zh) 芳基受体调制剂及其制备和使用方法
JP5559894B2 (ja) Ampkのチエノ[2,3−b]ピリジンジオンアクチベーターおよびその治療的使用
CN102060809B (zh) 一种大黄酸衍生物及其制备和用途
JP4599347B2 (ja) グルカゴンレセプターアンタゴニストとしての置換3−シアノチオフェンアセトアミド
WO2010012153A1 (zh) 根皮苷衍生物及其制备方法和应用
CN105228626A (zh) 用于诱导软骨形成的化合物和方法
CN116947756B (zh) 环丁烯二酮基喹啉类化合物及其制备方法、药物组合物和应用
WO2018215557A1 (fr) Composés inhibiteurs des canaux ioniques pour le traitement du cancer
JP5913651B2 (ja) 疼痛および他の疾患の処置のための化合物および方法
JP2022078094A (ja) Olig2活性の阻害
WO2019034153A1 (zh) 一种化合物,其药物组合物及其用途及应用
JP2010070514A (ja) ピラゾール誘導体及びその医薬用途
CN105175285B (zh) 多靶点型他米巴罗汀衍生物及其制备方法和应用
WO2024175662A1 (en) Flavagline derivatives as ras inhibitors
WO2024175659A1 (en) 3ah-cyclopenta[b]benzofuran-3a-yl as ras inhibitors
EP3689870A1 (en) Analgesic drug using pac1 receptor antagonistic drug
CN103037860A (zh) 用于治疗炎症性疾病的吡咯烷取代的黄酮
EP4186503A1 (en) Anti-inflammatory composition comprising benzofuran-based n-acylhydrazone derivatives
KR20130096639A (ko) 지방산 아미드 하이드롤라제의 조절제
WO2016173274A1 (zh) 芳香族法尼基类化合物及其应用
TW541295B (en) A novel substituted alkylteraamine derivative for use as tachykinin antagonist
US11345682B2 (en) Polymorph of HDAC6-selective inhibitor and application thereof
JP2009051731A (ja) 新規アスコクロリン誘導体化合物及びそれを含有する医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171020

WD01 Invention patent application deemed withdrawn after publication